New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 9, 2014
08:13 EDTOHRPOhr Pharmaceutical announces initiation of Phase II trial for OHR-005
Ohr Pharmaceutical announced the initiation of a Phase II investigator sponsored clinical trial, OHR-005, testing Squalamine Eye Drops in patients with diabetic macular edema. OHR-005 is a randomized, placebo controlled, investigator sponsored, multicenter Phase II clinical trial evaluating the effect of Squalamine Eye Drops in patients with DME. The primary endpoints will measure change in retinal thickness and change in Best Corrected Visual Acuity over 24 weeks. Secondary objectives include additional BCVA measurements, change in foveal thickness, evaluation of the need for rescue injections of ranibizumab and an assessment of the safety and tolerability of Squalamine Eye Drops.
News For OHRP From The Last 14 Days
Check below for free stories on OHRP the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for OHRP

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use